MELBOURNE, Australia, & MENLO PARK, Calif.--(BUSINESS WIRE)--ChemGenex Pharmaceuticals (ASX:CXS)(NASDAQ:CXSP) announced today updated results from its ongoing phase 2/3 trial of omacetaxine mepesuccinate (formerly known as Ceflatonin®) in chronic myeloid leukemia (CML) patients with the T315I mutation for whom there are currently no effective drug treatments.
